Search results for "chronic"

showing 10 items of 3309 documents

TpF1 from Treponema pallidum Activates Inflammasome and Promotes the Development of Regulatory T Cells

2011

Abstract Human syphilis is a multistage disease, with diverse and wide-ranging manifestations caused by Treponema pallidum. Despite the fact that a cell-mediated immune response takes part in the course of syphilis, T. pallidum often manages to evade host immunity and, in untreated individuals, may trigger chronic infection. With this study, we demonstrate for the first time, to our knowledge, that Treponema pallidum induces a regulatory T (Treg) response in patients with secondary syphilis and we found that the miniferritin TpF1, produced by the bacterium, is able to expand this response and promote the production of TGF-β. Accordingly, TpF1 stimulates monocytes to release IL-10 and TGF-β,…

AdultMaleMultiprotein complexInflammasomesVirulence FactorsCellsT-LymphocytesImmunologyAdult; Antigens Helminth; Cell Differentiation; Cells Cultured; Down-Regulation; Female; Humans; Inflammasomes; Inflammation Mediators; Male; Middle Aged; Monocytes; Syphilis; T-Lymphocytes Regulatory; Transforming Growth Factor beta; Treponema pallidum; Virulence FactorsDown-RegulationBiologyT-Lymphocytes RegulatoryMonocytesMicrobiologyProinflammatory cytokineImmune systemAntigenTransforming Growth Factor betaHelminthmedicineHumansImmunology and AllergySyphilisTreponema pallidumAntigensCells CulturedCulturedTreponemaCell DifferentiationInflammasomeMiddle Agedbiology.organism_classificationmedicine.diseaseRegulatoryChronic infectionAntigens HelminthImmunologyFemaleSyphilisInflammation Mediatorsmedicine.drugThe Journal of Immunology
researchProduct

Viral and host factors in the prediction of response to interferon-alpha therapy in chronic hepatitis C after long-term follow-up.

1998

Acute infection with hepatitis C virus (HCV) develops into a chronic hepatitis in about 50-70% of patients. Treatment of these patients with interferon-alpha (IFN-alpha) results in a sustained long-term response in only 15-20% but causes numerous unwanted side-effects in a higher percentage of patients. The aim of our study was to define host or viral parameters that would allow identification of responders and non-responders to IFN-alpha prior to the onset of treatment. We studied a group of 87 patients suffering from chronic hepatitis C who were treated with IFN-alpha. After long-term follow-up, 18 patients (21%) showed a sustained response to IFN-alpha therapy (normalization of serum tra…

AdultMaleNecrosisGenotypeHepatitis C virusAlpha interferonInflammationHepacivirusmedicine.disease_causeAntiviral AgentsFibrosisVirologyGenotypemedicineHumansViremiaHepatologymedicine.diagnostic_testbusiness.industryTumor Necrosis Factor-alphaInterferon-alphaHLA-DR AntigensHepatitis C ChronicMiddle AgedViral Loadmedicine.diseaseInfectious DiseasesTreatment OutcomeLiver biopsyImmunologyRNA ViralFemalemedicine.symptombusinessViral hepatitisFollow-Up StudiesJournal of viral hepatitis
researchProduct

Serum BLyS/BAFF predicts the outcome of acute hepatitis C virus infection.

2009

Summary.  B-lymphocyte stimulator/B activating factor (BLyS/BAFF) is a tumour necrosis factor-family cytokine that plays a key role in generating and maintaining the mature B-cell pool. BLyS/BAFF expression by macrophages is stimulated by interferon-γ and interleukin-10, and its serum levels are increased in chronic hepatitis C (CHC). The aim of this study was to assess serum levels of BLyS/BAFF in patients with acute hepatitis C (AHC) and correlate them with disease outcome. We studied 28 patients with AHC (14 males, mean age 59.3 ± 15 years), followed for at least 7 months since onset, comparing them with 86 CHC patients and 25 healthy blood donors (HBD). BLyS/BAFF levels were assessed at…

AdultMaleNecrosismedicine.medical_treatmentAcute hepatitis CVirusYoung AdultVirologyB-Cell Activating FactorMedicineHumansIn patientB-cell activating factorAgedAged 80 and overHepatologybusiness.industryHepatitis CHepatitis C ChronicMiddle Agedmedicine.diseaseHepatitis CChronic infectionInfectious DiseasesCytokineImmunologyFemaleAcute hepatitis Cmedicine.symptombusinessBiomarkersJournal of viral hepatitis
researchProduct

Progression of coronary artery calcification and cardiac events in patients with chronic renal disease not receiving dialysis

2011

We tested for the presence of coronary calcifications in patients with chronic renal disease not on dialysis and studied its progression in 181 consecutive non-dialyzed patients who were followed for a median of 745 days. Coronary calcifications (calcium score) were tallied in Agatston units by computed tomography, and the patients were stratified into two groups by their baseline calcium score (100 U or less and over 100 U). Survival was measured by baseline calcium score and its progression. Cardiac death and myocardial infarction occurred in 29 patients and were significantly more frequent in those patients with calcium scores over 100 U (hazard ratio of 4.11). With a calcium score of 10…

AdultMaleNephrologymedicine.medical_specialtySettore MED/09 - Medicina Internamedicine.medical_treatmentMyocardial Infarctioncardiovascular events chronic kidney disease coronary calcificationCoronary Artery DiseaseKaplan-Meier EstimateCohort StudiesCoronary artery diseasecardiovascular eventsRisk FactorsCalcinosisInternal medicinemedicineHumansMyocardial infarctionRenal Insufficiency ChronicDialysisAgedSettore MED/14 - Nefrologiabusiness.industryHazard ratiocoronary calcificationCalcinosisMiddle AgedPrognosismedicine.diseasecardiovascular eventSettore MED/45 - Scienze Infermieristiche Generali Cliniche E PediatricheSettore MED/11 - Malattie Dell'Apparato CardiovascolareSurgeryNephrologyDisease ProgressionCardiologyFemaleOriginal Articlebusinesschronic kidney diseaseKidney diseaseCalcification
researchProduct

Oxidative stress and inflammation in long-term renal transplanted hypertensives.

2006

INTRODUCTION Several studies have shown that chronic renal failure (CRF) is characterized by "accelerated atherosclerosis". More recent studies emphasize that inflammation and oxidative stress play a central role in atherosclerosis, and it is well-established that C-reactive protein (CRP) is a cardiovascular risk marker in the general population, in end-stage renal disease (ESRD) patients and in allograft recipients. METHODS We measured the serum concentration of high sensitivity CRP, TNFalpha, 8-iso-prostaglandin F2alpha (8-iso-PGF2alpha, an in vivo oxidative stress marker) in 15 CRF patients and in 15 transplant recipients. Exclusion criteria were age 65 years, smoking, diabetes mellitus …

AdultMaleNephrologymedicine.medical_specialtyTime FactorsPopulationRenal functionDinoprostchemistry.chemical_compoundInternal medicineDiabetes mellitusmedicineHumanseducationeducation.field_of_studyCreatinineTumor Necrosis Factor-alphabusiness.industryGeneral MedicineMiddle Agedmedicine.diseaseKidney Transplantationoxidative stress inflammation hypertension renal transplantationTransplantationOxidative StressC-Reactive ProteinEndocrinologyBlood pressurechemistryNephrologyCase-Control StudiesHypertensionKidney Failure ChronicInflammation MediatorsbusinessKidney disease
researchProduct

Lateralized and Bilateral Olfactory Function in Patients With Chronic Sinusitis Compared With Healthy Control Subjects

1998

Results of this study demonstrated that a new olfactory test, the "Sniffin' Sticks," can be used to distinguish hyposmic patients with chronic sinusitis (n = 63) from control subjects. Dirhinic testing yielded improved olfactory sensitivity compared with monorhinic testing. However, dirhinic results were not significantly different from results obtained for the best nostril.

AdultMaleOlfactory systemmedicine.medical_specialtyAdolescentNostrilNeurological disorderAudiologylaw.inventionRandomized controlled triallawSensory thresholdmedicineHumansIn patientSinusitisSinusitisAgedAged 80 and overbusiness.industryChronic sinusitismedicine.diseaseSurgerySmellmedicine.anatomical_structureOtorhinolaryngologySensory ThresholdsChronic DiseaseFemalebusinessThe Laryngoscope
researchProduct

Rationale and Design of the International Lymphoma Epidemiology Consortium (InterLymph) Non-Hodgkin Lymphoma Subtypes Project

2014

Background: Non-Hodgkin lymphoma (NHL), the most common hematologic malignancy, consists of numerous subtypes. The etiology of NHL is incompletely understood, and increasing evidence suggests that risk factors may vary by NHL subtype. However, small numbers of cases have made investigation of subtype-specific risks challenging. The International Lymphoma Epidemiology Consortium therefore undertook the NHL Subtypes Project, an international collaborative effort to investigate the etiologies of NHL subtypes. This article describes in detail the project rationale and design. Methods: We pooled individual-level data from 20 case-control studies (17 471 NHL cases, 23 096 controls) from North Ame…

AdultMaleOncologyCancer Researchmedicine.medical_specialtyAdolescentChronic lymphocytic leukemiaFollicular lymphomaNon-Hodgkin lymphoma (NHL)ArticleLymphoplasmacytic LymphomaYoung AdultRisk Factorsimmune system diseaseshemic and lymphatic diseasesInternal medicineEpidemiology of cancerPrevalencemedicineHumansAgedAged 80 and overMycosis fungoidesbusiness.industryLymphoma Non-HodgkinAustraliaWaldenstrom macroglobulinemiaGeneral MedicineMiddle Agedmedicine.diseaseNon-Hodgkin's lymphomaEuropeOncologyCase-Control StudiesEpidemiologic Research DesignNorth AmericaImmunologyInternational Lymphoma Epidemiology Consortiumhematologic malignancyFemaleMantle cell lymphomabusinessJNCI Monographs
researchProduct

Bcl-6 mutation status provides clinically valuable information in early-stage B-cell chronic lymphocytic leukemia

2004

In B-cell chronic lymphocytic leukemia (B-CLL), somatic mutation of IgVH genes defines a subgroup with favorable prognosis, whereas the absence of IgVH mutations is correlated with a worse outcome. Mutations of the BCL-6 gene are also observed in a subset of B-CLL, but the clinical significance of this molecular alteration remains uncertain. We examined the distribution of IgVH and BCL-6 gene mutations in 95 well-characterized patients with Binet stage A B-CLL, and correlated them with clinical, laboratory, cytogenetic findings and disease progression. Mutations of the BCL-6 gene were observed only in cases harboring mutated IgVH. Unexpectedly, coexistence of IgVH and BCL-6 mutations was co…

AdultMaleOncologyCancer Researchmedicine.medical_specialtyChronic lymphocytic leukemiaImmunoglobulin Variable RegionLocus (genetics)BiologyGene mutationDisease-Free SurvivalGermline mutationProto-Oncogene ProteinsInternal medicinemedicineHumansB-cell chronic lymphocytic leukemiaClinical significanceProspective StudiesGeneAgedAged 80 and overHematologyChromosomes Human Pair 11HematologyMiddle AgedPrognosismedicine.diseaseLeukemia Lymphocytic Chronic B-CellDNA-Binding ProteinsOncologyMutationImmunologyProto-Oncogene Proteins c-bcl-6FemaleChromosome DeletionChromosomes Human Pair 17Follow-Up StudiesTranscription FactorsLeukemia
researchProduct

Safety and efficacy of STI-571 (imatinib mesylate) in patients with bcr/abl-positive chronic myelogenous leukemia (CML) after autologous peripheral b…

2001

We examined safety and efficacy of STI-571 in 24 bcr/abl-positive patients with CML post PBSCT. At start of STI-571 therapy, nine patients presented in blast crisis (BC) or in accelerated phase (AP), and 15 in chronic phase (CP). Patients were evaluated for hematologic, cytogenetic and molecular response, survival and toxicity. In general, STI-571 was well tolerated in this heavily pretreated group of patients with a non-hematologic and hematologic toxicity profile similar to that observed in a previous phase I trial at comparable doses. Five of nine patients with CML in transformation (AP, BC) were evaluable for hematologic response. Two of five patients had transient reductions in WBC and…

AdultMaleOncologyCancer Researchmedicine.medical_specialtymedicine.medical_treatmentFusion Proteins bcr-ablAntineoplastic AgentsPhiladelphia chromosomeTransplantation AutologousPiperazinesLeukemia Myelogenous Chronic BCR-ABL Positivehemic and lymphatic diseasesInternal medicinemedicineHumansEnzyme InhibitorsChemotherapyABLbusiness.industryHematopoietic Stem Cell Transplantationbreakpoint cluster regionHematologyMiddle AgedProtein-Tyrosine Kinasesmedicine.diseaseCombined Modality TherapyHematologic ResponseBlood Cell CountPyrimidinesTreatment OutcomeImatinib mesylateOncologyBenzamidesToxicityImmunologyImatinib MesylateFemaleComplicationbusinessLeukemia
researchProduct

Estimation de l’incidence des hémopathies malignes en France entre 1980 et 2012

2016

International audience; BACKGROUND:The classification of hematological malignancies (HMs) has changed in recent decades. For the first time, the French network of cancer registries (Francim) provides estimates for incidence and trends of HM in France between 1980 and 2012 for major HM subtypes.METHODS:Incidence was directly estimated by modeling the incidence rates measured in the cancer registry area. For each HM subtype, a "usable incidence period" was defined a priori, corresponding to the years for which all the registries collected them in a homogeneous way. For both sexes and each HM subtype, age-period-cohort models were used to estimate national incidence trends.RESULTS:Overall in F…

AdultMaleOncologyPediatricsmedicine.medical_specialtyRegistryAdolescentEpidemiologyChronic lymphocytic leukemiaFollicular lymphoma[SDV.CAN]Life Sciences [q-bio]/Cancer[ SDV.CAN ] Life Sciences [q-bio]/CancerHematological malignanciesYoung Adult03 medical and health sciences0302 clinical medicineNeoplasmsInternal medicinemedicineHumansRegistriesAgedAged 80 and overbusiness.industryMyelodysplastic syndromesIncidence (epidemiology)IncidencePublic Health Environmental and Occupational HealthCancer[ SDV.SPEE ] Life Sciences [q-bio]/Santé publique et épidémiologieHémopathies malignesMiddle AgedPlasma cell neoplasmmedicine.disease3. Good healthLymphomaCancer registryTendancesHematologic Neoplasms030220 oncology & carcinogenesisFemale[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieFranceTrendsbusinessRegistre de population030215 immunology
researchProduct